ARTICLE | Clinical News

Genetics Institute, Genentech regulatory update

July 5, 1994 7:00 AM UTC

In April 1990, a U.S. District Court jury in Delaware found that NPA infringed three of the South San Francisco company's patents - 4,752,603, 4,766,075 and 4,853,330 - covering purified human tPA and recombinant tPA having the amino acid sequence of natural tPA. GENIZ, Cambridge, Mass., said NPA was engineered to produce a more potent form of plasminogen activator. ...